Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Jane L. Liesveld, MD, Kristen O'Dwyer, MD, Michael W. Becker, MD, Deborah Mulford, MD, Alison Walker, MD, Rui Chen, PhD, Jeremy Bechelli, MS, Karen Rosell, BS, Craig T. Jordan, PhD, Mohammad Minhajuddin, PhD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 3549.

https://doi.org/10.1182/blood.V120.21.3549.3549

Published: 2012

Journal Articles

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Deborah Mulford, MD, Scott E. Smith, MD, PhD, FACP, Gail Brown, MD, Lisa Meng, PhD, David P. Steensma, MD, Roger M. Lyons, MD, Ralph Boccia, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2778.

https://doi.org/10.1182/blood.V118.21.2778.2778

Published: 2011

Journal Articles

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Scott Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Ralph Boccia, MD, Han Myint, MD, Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail Brown, MD, Shelby A Young, RN, BSN, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2910.

https://doi.org/10.1182/blood.V116.21.2910.2910

Published: 2010

Journal Articles

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Jane L. Liesveld, MD, Karen Rosell, BS, Chaohui Lu, BS, Deborah Mulford, MD, Alison Walker, MD

Blood (2007) 110 (11): 4318.

https://doi.org/10.1182/blood.V110.11.4318.4318

Published: 2007

Journal Articles

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Meir Wetzler, MD, Selina Luger, MD, Larry D. Cripe, MD, Martin S. Tallman, MD, Ivana Gojo, MD, Deborah Mulford, MD, Maria R. Baer, MD, Alan F. List, MD, Pratik S. Multani, MD, Branimir I. Sikic, MD

Blood (2007) 110 (11): 299.

https://doi.org/10.1182/blood.V110.11.299.299

Published: 2007

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

NARROW

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only